Law360, New York (May 14, 2010, 2:58 PM ET) -- Medicis Pharmaceutical Corp. is considering another lawsuit over its patent for Solodyn in the wake of Mylan Inc.'s admission that one of its subsidiaries has filed another abbreviated new drug application for a generic version of the oral acne drug.
In a Form 8-K filing with the U.S. Securities & Exchange Commission on Thursday, Medicis said it had received notice from Mylan that Matrix Laboratories Ltd., an India-based, majority-owned subsidiary, filed an ANDA with the U.S. Food and Drug Administration for generic Solodyn in 65-milligram and...
Medicis Mulls New Solodyn IP Suit Against Mylan
To view the full article, take a free trial now.
